PIVOT Webinar

From Concept to Practice: How to tactically design a feasible outcomes-based contract in oncology

PIVOT Webinar:

From Concept to Practice: How to tactically design a feasible outcomes-based contract in oncology

Colorful lines intertwining into a rightwards pointing arrow

January 25, 2024

12:00pm – 1:00pm Eastern
Web conference

The session explored the essential components for successful contract design, addressing payer and developer uncertainties, and expediting patient access to innovative medicines.

Mark Trusheim, NEWDIGS Strategic Director, led the discussion on how to design a feasible outcomes-based oncology contract, focused on a fictional scenario: Astrotuminib, an oncology therapy for the treatment of Astrorenoma, a malignant kidney tumor. The panel tackling the task represented perspectives from developers, providers, and payers: Jamie FoleyRon Potts, and Michael Sherman. Each panelist provided key insights on the topic from their respective stakeholder viewpoints.

During the interactive discussion, the panel debated the various aspects of what a value-driven short-term milestone-based outcomes contract could look like, along with its challenges. Among them:

  • The identification of usable metrics, such as discontinuation rates
  • What data is relevant for the contract
  • How and where to obtain the data used to evaluate the outcomes
  • What party or parties are responsible for analysis of the data
  • Whether the data is sufficient, and of sufficient quality, for the contract

The 70+ attendees participated in polling and Q&A to share their perspectives and assist panelists with building a hypothetical outcomes-based contract (OBC) for Astrotuminib. The session gave participants practical insights into the issues for these contracts. Thanks to the stakeholder perspectives from the panel experts, participants delved into the need for careful analysis, collaboration between industry and payers and the importance of addressing data-related challenges not just for the design of the contract, but also for its implementation. The session closed with the panelists emphasizing that overcoming these challenges is important to improve patient access to transformative new therapies in oncology.

Webinar recording

Register now

January 25, 2024

12:00pm – 1:00pm Eastern
Web conference

The NEWDIGS PIVOT Project invites you to join us on Thursday, January 25, 2024 from 12:00-1:00 pm Eastern for an interactive webinar: From Concept to Practice: How to Tactically Design a Feasible Outcomes-Based Contract in Oncology. Dive deep into the essential components for successful contract design, addressing payer and developer uncertainties, and expediting patient access to innovative medicines.

In this 1-hour session, we will:

  • Introduce the concept of value-based contracts (VBCs), focusing on outcomes-based contracts (OBCs) in oncology and examples of how they have been used.
  • Explore industry and payer perspectives on OBCs, including best practices and engagement strategies.
  • Engage in a case study to design an effective OBC for a hypothetical oncology product.

Participants will benefit from industry insights and practical considerations from experts Mark Trusheim, Ron Potts, Jamie Foley, and Michael Sherman and have the opportunity to engage in real-time polling on key topics like contract metrics, data challenges, and contract reconciliation.

We encourage you to share this opportunity with your colleagues and collaborators interested in payment innovation and OBCs. Looking forward to working together to make a difference!

Register now

Who should attend

This session is ideal for payers, industry professionals, researchers, and consultants interested in expanding their understanding of OBCs and VBC feasibility and implementation challenges.

Speakers

Mark Trusheim 
Strategic Director, NEWDIGS

Ron Potts
Chief Medical Officer, 6 Degrees Health

Michael Sherman
Venture Partner, RA Capital Management

Jamie Foley
Global oncology value-based innovation biopharmaceutical industry professional

ImageImageTufts Medical Center logo

Panelists

Image

Mike Ciarametaro, MBA
Vice President Research,
National Pharmaceutical Council

Image

Dorothy Hoffman
External Engagement and Access Policy Lead,
Pfizer

Image

Gail Ryan, PharmD
Director, Pharmaceutical Transformation, Clinical Innovation
Point32Health

Image

Mark Trusheim, MS
Strategic Director, NEWDIGS;
Visiting Scientist, Sloan School of Management,
Massachusetts Institute of Technology

Agenda

Welcome and introductions

Mark Trusheim, Strategic Director, NEWDIGS; FoCUS Project Lead; Visiting Scientist at MIT Sloan School of Management
Gigi Hirsch, Executive Director, MIT Center for Biomedical Innovation (CBI); Director, NEWDIGS Initiative at MIT

Framing the Issues
Definition of Cell and Gene Therapies and their unique challenges/risks for self-insured employers including toolkit.

Mark Hansan, President and CEO, CareMetx

Drug development pipeline
Currently approved treatments and near-term pipeline of expected products

Colin Young, Director, Drug Development Pipeline Research, NEWDIGS FoCUS Project

Implications for stop-loss coverage

Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project and Moderator

New commercial solutions

Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project and Moderator

PANEL & DISCUSSION

Actions self-insured employers can take today

Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project and Moderator

Recap and conclusion

Mark Trusheim, Strategic Director, NEWDIGS; FoCUS Project Lead; Visiting Scientist at MIT Sloan School of Management

Registration